News Published: January 11, 2024

Major regulatory safety milestone reached in the TECVI-1 trial

VERIGRAFT starts 2024 off with a major progress in our TECVI-1 first-in-man trial: Half of the patients have been treated.

The trial also passed the final regulatory safety milestone in early January and is demonstrating maintained graft functionality at 12 months post treatment. These thrilling results help shape the future of advanced personalized tissue therapies in health care.

The TECVI-1 trial evaluates the safety of personalized tissue engineered veins (P-TEVs) with valves implanted in patients with severe chronic venous insufficiency (CVI).